Literature DB >> 31811034

Computationally Aided Discovery of LysEFm5 Variants with Improved Catalytic Activity and Stability.

Tsvetelina H Baryakova1, Seth C Ritter1, Daniel T Tresnak1, Benjamin J Hackel2.   

Abstract

Bacteriophage-derived lysin proteins are potentially effective antimicrobials that would benefit from engineered improvements to their bioavailability and specific activity. Here, the catalytic domain of LysEFm5, a lysin with activity against vancomycin-resistant Enterococcus faecium (VRE), was subjected to site-saturation mutagenesis at positions whose selection was guided by sequence and structural information from homologous proteins. A second-order Potts model with parameters inferred from large sets of homologous sequence information was used to predict the average change in the statistical fitness for mutant libraries with diversity at pairs of sites within the secondary catalytic shell. Guided by the statistical fitness, nine double mutant saturation libraries were created and plated on agar containing autoclaved VRE to quickly identify and segregate catalytically active (halo-forming) and inactive (non-halo-forming) variants. High-throughput DNA sequencing of 873 unique variants showed that the statistical fitness was predictive of the retention or loss of catalytic activity (area under the curve [AUC], 0.840 to 0.894), with the inclusion of more diverse sequences in the starting multiple-sequence alignment improving the classification accuracy when pairwise amino acid couplings (epistasis) were considered. Of eight random halo-forming variants selected for more sensitive testing, one showed a 1.8 (±0.4)-fold improvement in specific activity and an 11.5 ± 0.8°C increase in melting temperature compared to those of the wild type. Our results demonstrate that a computationally informed approach employing homologous protein information coupled with a mid-throughput screening assay allows for the expedited discovery of lysin variants with improved properties.IMPORTANCE Broad-spectrum antibiotics can indiscriminately kill most bacteria, including commensal species that are a part of the normal human flora. This can potentially lead to the proliferation of drug-resistant bacteria upon elimination of competing species and to unwanted autoimmune effects in patients. Bacteriophage-derived lysin proteins are an alternative to conventional antibiotics that have coevolved alongside specific bacterial hosts. Lysins are capable of targeting conserved substrates in the bacterial cell wall essential for its viability. To engineer these proteins to exhibit improved therapeutically relevant properties, homology-guided statistical approaches can be used to identify compelling sites for mutation and to quantify the functional constraints acting on these sites to direct mutagenic library creation. The platform described herein couples this informed approach with a visual plate assay that can be used to simultaneously screen hundreds of mutants for catalytic activity, allowing for the streamlined identification of improved lysin variants.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Potts model; covariation; epistasis; homology; lysin; vancomycin-resistant Enterococcus

Year:  2020        PMID: 31811034      PMCID: PMC6997734          DOI: 10.1128/AEM.02051-19

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN: 0099-2240            Impact factor:   4.792


  50 in total

Review 1.  Bacteriophage lysis: mechanism and regulation.

Authors:  R Young
Journal:  Microbiol Rev       Date:  1992-09

2.  How mutational epistasis impairs predictability in protein evolution and design.

Authors:  Charlotte M Miton; Nobuhiko Tokuriki
Journal:  Protein Sci       Date:  2016-01-22       Impact factor: 6.725

3.  Mutation effects predicted from sequence co-variation.

Authors:  Thomas A Hopf; John B Ingraham; Frank J Poelwijk; Charlotta P I Schärfe; Michael Springer; Chris Sander; Debora S Marks
Journal:  Nat Biotechnol       Date:  2017-01-16       Impact factor: 54.908

4.  Using a Novel Lysin To Help Control Clostridium difficile Infections.

Authors:  Qiong Wang; Chad W Euler; Aurelia Delaune; Vincent A Fischetti
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

5.  Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme.

Authors:  D Nelson; L Loomis; V A Fischetti
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

6.  SwiftLib: rapid degenerate-codon-library optimization through dynamic programming.

Authors:  Timothy M Jacobs; Hayretin Yumerefendi; Brian Kuhlman; Andrew Leaver-Fay
Journal:  Nucleic Acids Res       Date:  2014-12-24       Impact factor: 16.971

7.  Structural basis for peptidoglycan binding by peptidoglycan recognition proteins.

Authors:  Rongjin Guan; Abhijit Roychowdhury; Brian Ember; Sanjay Kumar; Geert-Jan Boons; Roy A Mariuzza
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-30       Impact factor: 11.205

8.  Structural basis of cell wall cleavage by a staphylococcal autolysin.

Authors:  Sebastian Zoll; Bernhard Pätzold; Martin Schlag; Friedrich Götz; Hubert Kalbacher; Thilo Stehle
Journal:  PLoS Pathog       Date:  2010-03-12       Impact factor: 6.823

9.  HMMER web server: interactive sequence similarity searching.

Authors:  Robert D Finn; Jody Clements; Sean R Eddy
Journal:  Nucleic Acids Res       Date:  2011-05-18       Impact factor: 16.971

Review 10.  The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation.

Authors:  Amy Langdon; Nathan Crook; Gautam Dantas
Journal:  Genome Med       Date:  2016-04-13       Impact factor: 11.117

View more
  1 in total

1.  A Platform for Deep Sequence-Activity Mapping and Engineering Antimicrobial Peptides.

Authors:  Matthew P DeJong; Seth C Ritter; Katharina A Fransen; Daniel T Tresnak; Alexander W Golinski; Benjamin J Hackel
Journal:  ACS Synth Biol       Date:  2021-09-10       Impact factor: 5.249

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.